Fingerprint
Dive into the research topics of 'A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically